Biohackr: Track your protocol. Model the curve.

Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.

Overview

Kisspeptin-10 is a synthetic decapeptide (10 amino acids), the shortest biologically active fragment of the endogenous neuropeptide kisspeptin (also called metastin), which functions as the master regulator of mammalian reproductive function. The compound represents an unusual entry in this library because the active ingredient is essentially an endogenous human peptide, and kisspeptin-10 binds the KISS1R receptor (also called GPR54) on hypothalamic GnRH neurons to trigger pulsatile GnRH release, making it the most upstream HPG-axis modulator available pharmacologically.

The kisspeptin system was identified in the early 2000s as the critical "gatekeeper" of reproductive function: 2003 discovery that mutations in KISS1R cause congenital hypogonadotropic hypogonadism (CHH); established as essential for puberty initiation, GnRH pulsatility, and gonadal function; therapeutic potential quickly recognized for reproductive disorders, infertility, and HPG axis manipulation.

Kisspeptin-10 has been extensively studied in basic and translational research but has limited human Phase 2/3 development. Most human clinical research has used kisspeptin-54 (the longer parent fragment), the workhorse of Professor Waljit Dhillo's group at Imperial College London, where the majority of published human kisspeptin evidence originates. Kisspeptin-10 has been directly compared with kisspeptin-54 and shown to produce somewhat lower LH/FSH responses (approximately 2–3 fold lower than GnRH; comparable to kisspeptin-54 at lower potency).

Forms

Available forms & half-lives

Form	Approximate half-life
Intravenous Kisspeptin-10	Short: minutes (rapid clearance)
Subcutaneous Kisspeptin-10	Somewhat extended but still short
Intranasal Kisspeptin-10 (experimental)	Lower bioavailability

What it does

Main effects

Most upstream HPG-axis modulator available pharmacologically: KISS1R (GPR54) agonism on hypothalamic GnRH neurons; triggers pulsatile GnRH release, which then drives LH/FSH release from pituitary; works upstream of GnRH analogs (gonadorelin), SERMs (clomiphene, tamoxifen), and hCG
Endogenous human peptide: identical sequence to the natural KISS1-derived decapeptide (residues 112–121); no immunogenicity concerns; well-understood physiological context
Potent LH and FSH stimulation in men: George et al. 2011 (PMID: 21632815) demonstrated LH stimulation and increased LH pulse frequency with IV kisspeptin-10
Diagnostic discrimination of hypothalamic vs pituitary hypogonadism: kisspeptin (predominantly kisspeptin-54 in published studies) perfectly discriminates HH patients from eugonadal men (AUC ROC 1.0); more discriminatory than GnRH (AUC 0.82)
IVF and fertility applications: Phase 2 evidence for kisspeptin-54 as ovulation trigger (alternative to hCG); reduced OHSS risk; egg quality maintained
Brain modulation in sexual and emotional processing regions: Imperial College London fMRI studies (JAMA Network Open 2022, 2023); suggests broader CNS effects beyond HPG axis; possible HSDD relevance
"Master regulator of mammalian reproductive function": 2003 discovery that KISS1R/GPR54 mutations cause congenital hypogonadotropic hypogonadism established kisspeptin as essential for puberty initiation
Theoretical PCT application: could restore HPG axis after AAS-induced suppression by directly activating KISS1R on GnRH neurons; NOT validated in controlled clinical trials
C-terminal RFamide motif (Arg-Phe-NH₂) is the minimum bioactive structure shared with longer kisspeptin fragments (kisspeptin-14, -13, -10)

What to watch for

Common side effects

Most clinical research has used kisspeptin-54, NOT kisspeptin-10: substantial evidence asymmetry; kisspeptin-10-specific clinical outcomes are less validated than the broader kisspeptin literature suggests; Imperial College London (Dhillo lab) has used kisspeptin-54 as the workhorse
Direct comparison showed kisspeptin-10 produces ~3-fold LOWER LH than GnRH (and somewhat lower than kisspeptin-54) at equivalent doses; less potent than direct GnRH stimulation
Short half-life (minutes): requires IV infusion or frequent SC dosing; unprotected peptide structure (no D-amino acids, no protective modifications) susceptible to peptidase degradation
No regulatory approval anywhere: investigational/research stage; TAK-448 (Takeda) and other analogs in earlier development but no late-stage commercial development to approval
"PCT" application (popular non-medical use) lacks controlled trial evidence: theoretical mechanism is sound but unvalidated; optimal dosing for PCT not established; comparison to established PCT (clomiphene, hCG, enclomiphene) unstudied; long-term outcomes unknown
Generally well-tolerated in human research: no major adverse events at clinical doses; favorable safety profile based primarily on kisspeptin-54 data
Injection site reactions (mild pain, redness with SC use; IV infusion site reactions): generally mild
Mild headache, dizziness: uncommon; rare
Effects on HPG axis (LH, FSH, downstream sex hormones): intended mechanism but may not be desired in all contexts (e.g., users on hormonal therapy)
Theoretical cancer history concern: KISS1 was originally identified as a metastasis suppressor gene (1996); pregnancy elevates kisspeptin dramatically without obvious cancer effects; no epidemiological signal documented but caution in cancer history
Requires intact pituitary AND gonads to produce downstream effects: won't work in pituitary or gonadal failure (only hypothalamic dysfunction)
Long-term safety data is essentially absent: most studies are hours to weeks duration; no multi-year clinical trials
Quality concerns for research chemical sources: identity verification, concentration variability, sterility, storage stability (cold chain typically needed)
Pregnancy avoided in standard clinical use; caution in hormone-sensitive cancers; limited data in cardiovascular disease, renal/hepatic impairment
WADA status: Not currently specifically prohibited, but related GnRH analogs are prohibited; status could change

Key facts

Key facts worth knowing

Kisspeptin-10 is a decapeptide (10 amino acids) corresponding to C-terminal residues 112–121 of the 145-amino acid kisspeptin precursor polypeptide encoded by the KISS1 gene. The sequence ends in RFamide (arginine-amidated phenylalanine), characteristic of the RFamide peptide family. Sequence: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂.
Endogenous origin matters: Unlike most peptides in the library (synthetic analogs, foreign protein derivatives, etc.), kisspeptin-10 is essentially identical to a naturally occurring human peptide fragment. The KISS1 gene encodes kisspeptin-54, which is enzymatically processed to shorter active fragments including kisspeptin-14, kisspeptin-13, and kisspeptin-10, all sharing the same C-terminal decapeptide and bioactivity.
Mechanism is KISS1R (GPR54) agonism on hypothalamic GnRH neurons. KISS1R activation triggers GnRH release, which then acts on pituitary gonadotrophs to release LH and FSH. This places kisspeptin upstream of GnRH, GnRH analogs (gonadorelin), and SERMs (clomiphene, tamoxifen) in the HPG axis.
Discovery story: KISS1 was originally identified as a metastasis suppressor gene (hence one name "metastin") in 1996. The reproductive role was discovered only in 2003 when GPR54/KISS1R mutations were identified in patients with congenital hypogonadotropic hypogonadism (CHH). This connected the molecular biology to clinical endocrinology and launched the field of kisspeptin reproductive research. PMID: 12944565
Clinical research is led by Professor Waljit Dhillo's group at Imperial College London. The Dhillo lab has published the majority of human kisspeptin trials, primarily using kisspeptin-54 rather than kisspeptin-10. Research areas include diagnostic testing for hypogonadotropic hypogonadism, IVF and fertility applications, hypoactive sexual desire disorder (HSDD), polycystic ovary syndrome (PCOS), various reproductive disorders.
Kisspeptin-10 vs kisspeptin-54 comparison: Both activate KISS1R; kisspeptin-10 has intrinsic bioactivity similar to longer fragments; comparable potency at equimolar doses; kisspeptin-10 has shorter half-life than kisspeptin-54; kisspeptin-10 has more rapid onset of action; kisspeptin-54 has substantially more human trial evidence; kisspeptin-10 has greater theoretical pharmaceutical development potential (smaller, more agonists and antagonists developed). PMID: 21632815 PMC: 4507333
Position in the HPG axis relative to other modulators: Kisspeptin acts furthest upstream, on KISS1R on hypothalamic GnRH neurons, whereas GnRH analogs such as gonadorelin act at the pituitary and SERMs such as clomiphene and tamoxifen act through estrogen-receptor blockade. Recovery of the axis after exogenous testosterone or AAS suppression has no controlled clinical trial evidence for kisspeptin, and no comparative data against hCG or the SERMs exists.
Imperial College fMRI research: Kisspeptin modulates brain activity in regions governing sexual and emotional processing; JAMA Network Open 2022 and 2023 RCTs; brain imaging, not definitive outcomes trials; suggests broader CNS effects beyond HPG axis. WADA status: Not currently on the WADA Prohibited List, but related compounds (GnRH analogs) are prohibited; status could change.

Legal status